focus -WSS

focus

author：fashion 2025-09-10 08:44:25 - browse：3175

Adam's take main illustration — Molly Ferguson/STAT

Some day-after thoughts on Bristol Myers Squibb acquiring Mirati Therapeutics:

A take-under deal feels meh for biotech sector sentiment.Bristol is paying $58 per share in cash for Mirati, which closed Friday at $60. Granted, Mirati was trading in the $30 range in September, so from there, the roughly 50% premium isn’t terrible. But as Mizuho strategist Jared Holz pointed out, investors would liked to have seen Mirati go for $75-$100 per share.

With the closely watched XBI biotech index down 13% for the year, every M&A deal helps improve sentiment, but this one — maybe just a little. Bristol is paying $4.8 billion in cash to acquire Mirati, or $3.7 billion after accounting for Mirati’s cash. It’s a small bolt-on acquisition for Bristol, which isn’t overpaying.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Wegovy trial has doctors encouraged over new possibilities

explore

WSS

Wegovy trial has doctors encouraged over new possibilities

Wayne Brady comes out as pansexual: 'Free to love whomever I want'

'Little Tech' descents on D.C., wanting a say in how AI is regulated

CMS got Medicare Advantage quality rating wrong, judge rules

A biotech analyst on neuroscience, placebo effect, not over

American woman, child freed after being kidnapped in Haiti last month

leisure time

focus

focus

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

ASCO Daily Recap: CAR

DIEP, the 'gold standard' of breast reconstruction, is under threat

How CO2 helps viruses stay alive longer in the air

State Dept. review finds Biden bears some blame for Afghanistan failures

Illumina board agrees to spin off Grail, as divestment plans proceed

Hollywood unions extend contract negotiations for actors

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Wegovy trial has doctors encouraged over new possibilities

hotspot

Take antibiotics after sex, CDC recommends for certain risk groups

ASCO Takeaways: Winners, snoozers, and the art of cancer care

South Korea throws huge K

STAT wants to know your pick for a great summer read or listen

Shkreli is convicted of fraud. Can pharma finally slam the door on him?

CMS got Medicare Advantage quality rating wrong, judge rules

leisure time

Wikipedia

explore

knowledge